减少依托咪酯诱导致肌阵挛的药物研究进展  

Research Progress of Drugs for Reducing Myoclonus Induced by Etomidate

作　　者：徐亚军 郑军[1] 

机构地区：[1]延安大学附属医院麻醉科,陕西 延安

出　　处：《医学诊断》2020年第4期204-210,共7页Medical Diagnosis

摘　　要：随着依托咪酯新剂型在临床上的应用,大多副作用都已完全解决或部分解决,但其引起的肌阵挛至今尚未解决,且麻醉诱导时发生率高达50%到80%。只有充分了解肌阵挛的机制、预防药物的剂量以及配伍,才可有效减少肌阵挛的发生。回顾了减少肌阵挛发生的药物,对比应用各药物的优缺点,介绍了现有文献中明显抑制肌阵挛发生的剂量以及可能的发生机制,为临床应用提供参考。指出了减少依托咪酯引起的肌阵挛的最佳方案和最佳剂量亟待国内外研究人员解决的问题。With the clinical application of the new formulation of etomidate, most of the side effects have been completely resolved or partially resolved, but the myoclonus caused by it has not yet been resolved, and the incidence of anesthesia induction is as high as 50% to 80%. Only by fully understanding the mechanism of myoclonus, the dosage and compatibility of preventive drugs, can the occurrence of myoclonus be effectively reduced. The drugs that reduce the occurrence of myoclonus are reviewed, the advantages and disadvantages of each drug are compared, and the doses and possible mechanisms in the existing literature that can significantly inhibit the occurrence of myoclonus are introduced to provide references for clinical applications. This paper pointed out the best plan to reduce etomidate-induced myoclonus and the best dose of problems that need to be solved by domestic and foreign researchers.

关 键 词：依托咪酯 麻醉诱导 肌阵挛 阿片类药物 右美托咪定 

分 类 号：R28[医药卫生—中药学]